Emilio Bria
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 206 publications
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors.
Journal: Critical reviews in oncology/hematology
Published: January 13, 2023
Effect of exercise on functional capacity in patients with advanced cancer: A meta-analysis of randomized controlled trials.
Journal: Critical reviews in oncology/hematology
Published: May 11, 2022
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study.
Journal: Breast (Edinburgh, Scotland)
Published: July 02, 2021
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model.
Journal: Breast (Edinburgh, Scotland)
Published: November 04, 2019
Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma.
Journal: International journal of molecular sciences
Published: September 24, 2019
Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story.
Journal: Cancers
Published: July 31, 2019
Exploiting MET dysregulation in EGFR-addicted non-small-cell lung carcinoma: a further step toward personalized medicine.
Journal: Translational lung cancer research
Published: February 02, 2019
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 10, 2019
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.
Journal: Cancer biology & therapy
Published: November 08, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Journal: JAMA oncology
Published: September 08, 2018
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer.
Journal: Targeted oncology
Published: September 01, 2018
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?
Journal: Seminars in oncology
Published: August 13, 2018
Last Updated: 09/26/2026